|
March 13, 2006 Categories: Uncategorized Posted by admin
The CYPHER® Sirolimus-eluting Coronary Stent reduced the risk of target vessel failure (TVF) by almost half in patients who suffered a heart attack (acute myocardial infarction or AMI) compared to those who were treated with the current standard of care (balloon angioplasty and a bare metal stent), according to data presented today during a late-breaking clinical trials session at the 2006 American College of Cardiology Scientific Session.
Full news
|
|
